Submission of rolling BLA request for OST-HER2 to FDA to begin in Sep 2025

“It is clear from the End of Phase 2 Meeting that FDA is committed to finding paths forward to bring new therapies forward for osteosarcoma given the continued high mortality rates in this rare pediatric cancer,” said Paul Romness, MHP, Chair & CEO of OS Therapies. “We have already begun the work of preparing responses to FDA’s comments stemming from the meeting and look forward to beginning the rolling BLA submission later this quarter. We will continue the highly productive ongoing dialogue we have with FDA as it relates to OST-HER2’s potential to improve both Event Free Survival and Overall Survival in the fully resected, pulmonary metastatic osteosarcoma setting. We expect that the October 10th, 2025 workshop FDA and OSI are holding will provide the opportunity for stakeholders to coalesce around the key outcome measures that are clinically meaningful for the brave patients, their families and clinicians who help manage this difficult to treat patient population.”

Share:

More News

Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for zipalertinib in combination with platinum-based chemotherapy for the treatment of patients with previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20

“This collaboration reflects our conviction that atebimetinib has the potential to become an essential backbone therapy in a broad range of combinations across MAPK-driven cancers,” said Ben Zeskind, Immuneering CEO and co-founder. “Atebimetinib’s unique tolerability profile and broad activity make it well suited to combine with a wide range of

“These final updated results provide continued evidence of the potential for γδ T cell therapies to drive activity and improve outcomes for patients,” said William Ho, CEO and co-founder of IN8bio. “The clinical outcomes and observed activity are supported by our correlative analysis, including histopathology, demonstrating the expansion and persistence

“Patients with RAS-mutated mCRC have no first-line therapies specifically approved for their disease, and Fast Track designation reflects the potential of onvansertib to address this serious unmet need,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Our randomized Phase 2 data give us confidence that onvansertib